Firms
Theme

PAYX

Paychex Inc · NASDAQ

News

8 latest

Zacks Investment Research

Paychex (PAYX) Up 17% Since Last Earnings Report: Can It Continue?

Paychex reported strong Q1 fiscal 2027 earnings, beating consensus estimates with adjusted EPS of $1.34 and revenues of $1.63 billion. The company raised guidance for PEO and Insurance Solutions revenue growth to 7-8%. However, analyst estimates have been trending downward over the past month, and the stock received a Zacks Rank #3 (Hold) rating with a subpar VGM Score of D, suggesting in-line returns ahead.

Zacks Investment Research

PAYX Shares Rise 17.7% in Six Months: Here's What You Should Know

Paychex (PAYX) has gained 17.7% over six months, supported by AI-driven innovation through its WISE platform, the Paycor acquisition expanding cross-selling opportunities, and strong financial performance with 6% revenue growth and 10% adjusted EPS growth in Q1 fiscal 2027. The company maintains a Zacks Rank #3 (Hold) with management reaffirming 5-6% revenue growth and 44% operating margin targets for fiscal 2027.

Zacks Investment Research

Accenture's Q4 Earnings Beat Estimates, Revenues Increase 6% Y/Y

Accenture delivered impressive Q4 fiscal 2026 earnings of $3.29 per share (up 8.6% YoY) and revenues of $18.7B (up 6.2% YoY), both beating consensus estimates. The company projects FY27 local-currency revenue growth of 3-6% with EPS of $14.39-$14.81.

GlobeNewswire Inc.

Paychex Earns 5-Star Rating on Newsweek's America's Greatest Companies 2026 List

Paychex has been recognized on Newsweek's America's Greatest Companies 2026 list with a 5-out-of-5-star rating, evaluated across financial strength, market performance, innovation, and environmental sustainability. The company is scaling its AI-powered WISE engine, which is helping over 50,000 businesses catch approximately 90% of payroll errors before they occur.

Mentions PAYX

Zacks Investment Research

NSP Benefits From HRScale Adoption Amid High Competition

Insperity reported Q2 2026 adjusted earnings of 34 cents per share, up 31% YoY and beating consensus by 3%, with revenues of $1.69B. The company expanded HRScale adoption to nearly 8,000 WSEEs and increased working capital to $180M. However, the company faces headwinds from intense PEO competition, a 1% decline in average paid WSEEs, and elevated debt levels of $419M.

Zacks Investment Research

Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity

IQVIA reported Q2 2026 adjusted EPS of $3.15, up 12.1% YoY and beating consensus by 4.3%, with revenues of $4.37B up 8.7% and exceeding estimates. R&D Solutions new bookings surged 19% to $3.2B. However, the company faces liquidity concerns with a current ratio of 0.71 and net leverage at 3.6X adjusted EBITDA.

Zacks Investment Research

FactSet's Q4 Earnings Beat Estimates, Revenues Increase 6.3% Y/Y

FactSet Research Systems (FDS) delivered Q4 FY2026 results beating expectations with adjusted EPS of $4.52 (up 11.6% YoY) and revenues of $634.7M (up 6.3% YoY). Organic ASV grew 7% to $2.57B with retention above 95%.

Zacks Investment Research

ACN Set to Report Q4 Earnings: Here's What Investors Should Know

Accenture is expected to report Q4 fiscal 2026 results on October 1 with revenues estimated at $18B (up 5.6% YoY) and EPS projected at $3.19 (up 5.3% YoY). Growth is anticipated across most segments driven by AI demand and consulting capabilities, though Asia Pacific revenues are expected to decline 26.4%. The company has a positive earnings surprise history and an Earnings ESP of +0.31%.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $PAYX · 0 threads

Sign in to post on $PAYX

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev